Seres Therapeutics (MCRB)
(Delayed Data from NSDQ)
$0.83 USD
+0.08 (11.08%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.84 +0.02 (1.82%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Seres Therapeutics (MCRB) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$8.75 | $15.00 | $5.00 | 1,082.43% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Seres Therapeutics comes to $8.75. The forecasts range from a low of $5.00 to a high of $15.00. The average price target represents an increase of 1% from the last closing price of $0.74.
Analyst Price Targets (4 )
Broker Rating
Seres Therapeutics currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, five are Strong Buy, representing 83.33% of all recommendations. A month ago, Strong Buy represented 83.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.33 | 1.33 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/1/2024 | Chardan Capital Markets | Keay T Nakae | Strong Buy | Strong Buy |
11/2/2023 | Canaccord Genuity | John L Newman | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 6 |
Average Target Price | $8.75 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 75 of 252 |
Current Quarter EPS Est: | -0.36 |